All Posts by
The 2018 Antonio Champalimaud Vision Award recognizes Hauswirth and his colleagues for developing the first successful gene therapy to cure an inherited human disease. The disease, Leber congenital amaurosis Type 2, or LCA 2, is caused by a genetic defect. The 1 million euro (approximately $1.2 million) award from the Portugal-based D.
Dr. Hauswirth was recently invited by Pope Francis to speak at the Vatican Symposium on Regenerative Medicine and its Cultural Impact. Created by the Stem Cell for Life Foundation and the Vatican’s Pontifical Council for Culture, this symposium gathered a mix of scientists, philosophers and medical philanthropists world wide. Sessions were…
The University of Florida announces the creation of the Ocular Gene Therapy Core as an adeno-associated virus (AAV) production facility. This core service provides customizable AAV production to match your gene delivery needs. For more details, visit ogtc.eye.ufl.edu/…
Please join us on Monday, November 2nd for this years symposium “From Bench to Branding: Bringing Research Discoveries to Life”. Details on our distinguished speakers and a schedule of events are below:…
Drs. Shannon Boye, William Hauswirth and Sanford Boye were honored this year at the Univerisy of Florida’s Celebration of Innovation for successfully transferring their world-class research to a commercial partner. The University of Florida ranks among the nation’s leaders at transferring technology to partners who turn these discoveries into commercial products…
William Hauswirth, Ph.D. was co-awarded the 2014 OIS Innovator Award in Chicago at the Ophthalmology Innovation Summit, a full day pre-meeting of the American Academy of Ophthalmology annual meeting. He shared the award with Dr. Nick Myzyczka, Ph.D. also from the University of Florida and Susan…
Dr. Boye’s grant will help support development of an AAV- based gene therapy to treat the retinal phenotype of the severe deaf/blinding disease, Usher syndrome type 1B, which is caused by mutations in the gene MYO7A. Because MYO7A is large, the therapy…
Dr. Shannon Boye is featured in an article from Ophthalmology Times about advances in the AAV vector for retinal gene therapy.
Dr. Shannon Boye, Assistant Professor in the University of Florida’s Department of Ophthalmology was recently awarded a $900,000 grant from Genzyme, a division of Sanofi, to develop a treatment for a severe form of childhood blindness called Leber congenital amaurosis-1 (LCA1). This disease is caused by genetic mutations which prevent…
